Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age25-60
SponsorAin Shams University
About this trial
The investigators will compare the efficacy of Interleukin-6 (IL-6) as a better indicator than procalcitonin in burn patients with sepsis or septic shock regarding success of treatment and early ICU discharge.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence.
patients with burn percentage of 25% to 50% of total body surface area
patients with second to third degree burns
ASA 1 and ASA 2 patients
Disqualifiers
Burn percentage more than 50% or less than 25% of total body surface area
Having autoimmune diseases
Cancer patients
ASA 3 and ASA 4 patients
Trial design
Design model
Single group
Treatments tested in this trial
Interleukin 6
Diagnostic testInterleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10
Treatment groups
70 Participants
are divided into 1 treatment groupGroup A: Burn ICU patientsExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Occurrence of sepsis and septic shock
Prediction of occurrence of sepsis and septic shock
Time frame
From day 1 to day 10 in burn ICUSecondary outcomes
1
Length of ICU stay
Response to treatment and length of ICU stay for over one month
Time frame
One month after ICU admissionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov